Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
Rhea-AI Summary
Cellectis announces voting rights for March 2024 with a total of 77,889,229 voting rights from 71,953,535 shares in the capital, listed on Euronext Growth with ISIN code FR0010425595.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
-
Rhea-AI Summary
Cellectis announces voting rights for February 2024 with a total of 77,686,895 voting rights and 71,751,201 shares in the capital. The company's ISIN code is FR0010425595, listed on Euronext Growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
-
Rhea-AI Summary
Cellectis (CLLS) reports a total number of shares in the capital and voting rights as of January 31, 2024. The company's ISIN code is FR0010425595 and is listed on Euronext Growth. Media and investor relations contacts are provided for further information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has announced the drawdown of the second tranche of €15 million under a credit facility agreement with the European Investment Bank. The company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates. As a condition to the disbursement, the company issued warrants to the EIB, allowing them to subscribe for one ordinary share of the company at a specific price. The total number of shares issuable upon exercise of the warrants represents circa 2% of the company’s outstanding share capital at their issuance date. The tranche will mature in six years and accrue interest at a rate of 7% per annum. The company also has the option to drawdown a third tranche of up to €5 million, subject to certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
-
Rhea-AI Summary
Cellectis (Euronext Growth: FR0010425595) reports a total number of shares in the capital as 71,751,201 and a total number of voting rights as 77,686,718 as of December 31, 2023. For further information, media contact is Patricia Sosa Navarro at +33 (0)7 76 77 46 93, media@cellectis.com. Investor Relations contacts are Arthur Stril at +1 (347) 809 5980, investors@cellectis.com and Ashley R. Robinson at +1 617 430 7577.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) held a shareholders general meeting at which resolutions 1 through 5 and 7 and 8 were adopted and resolution 6 was rejected. Shareholders supported a contemplated $140M additional investment by AstraZeneca, subject to clearance from the French Ministry of Economy. Mr. Marc Dunoyer and Dr. Tyrell Rivers were approved as directors of the Cellectis board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS) reports a total number of 71,751,201 shares in the capital and 77,686,109 voting rights as of November 30, 2023. For further information, please contact Media Chief of Staff Patricia Sosa Navarro at +33 (0)7 76 77 46 93 or media@cellectis.com, and Investor Relations Chief Business Officer Arthur Stril at +1 (347) 809 5980 or investors@cellectis.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
-
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) to hold a general meeting on December 22, 2023, at 2:30 p.m. CET at the Biopark auditorium in Paris, France. The notice of meeting, agenda, resolutions, and terms of participation are available on the Cellectis website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
-
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) has signed a binding Subsequent Investment Agreement with AstraZeneca regarding the additional equity investment of $140M previously announced. AstraZeneca will subscribe to 10,000,000 'class A' convertible preferred shares and 18,000,000 'class B' convertible preferred shares at $5.00 per share. The approval of an extraordinary shareholders’ meeting of Cellectis and clearance from the French Ministry of Economy are required before the closing of the investment, which is expected to result in AstraZeneca owning approximately 44% of the share capital and 30% of the voting rights of Cellectis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has signed strategic collaboration and investment agreements with AstraZeneca. The collaboration will leverage Cellectis' gene editing technologies to develop next-generation therapeutics in areas of high unmet need. Cellectis' clinical-stage assets will remain under its ownership. The company also provided updates on its clinical trials and preclinical programs, including the BALLI-01 trial evaluating UCART22 and the NATHALI-01 trial evaluating UCART20x22. Cellectis has a cash position of $721 million as of September 30, 2023, providing a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.41%
Tags
Cellectis